Library — CHDR

Search

Filter

Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors.

Ducore J, Lawrence JB, Simpson M, Boggio L, Bellon A, Burggraaf J, Stevens J, Moerland M, Frieling J, Reijers J, Wang M

Haemophilia : the official journal of the World Federation of Hemophilia, 2018 Feb; 23(6):844-851

View publication
A PK-PD model-based assessment of sugammadex effects on coagulation parameters.

Bosch R, van Lierop MJ, de Kam PJ, Kruithof AC, Burggraaf J, de Greef R, Visser SA, Johnson-Levonas AO, Kleijn HJ

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2016 Mar

View publication
Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjects.

De Kam PJ, Kruithof AC, van Lierop MJ, Moerland M, Dennie J, Troyer MD, Langdon RB, Gutstein DE, Burggraaf J, El Galta R

International journal of clinical pharmacology and therapeutics, 2014 Jul; 52(8):631-41

View publication
Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects.

De Kam PJ, Grobara P, Prohn M, Höppener F, Kluft C, Burggraaf J, Langdon RB, Peeters P

International journal of clinical pharmacology and therapeutics, 2014 Feb; 52(3):227-36

View publication
No clinically relevant interaction between sugammadex and aspirin on platelet aggregation and coagulation parameters.

de Kam PJ, El Galta R, Kruithof AC, Fennema H, van Lierop MJ, Mihara K, Burggraaf J, Moerland M, Peeters P, Troyer MD

International journal of clinical pharmacology and therapeutics, 2013 Nov; 51(12):976-85

View publication
Preincubation in the Prothrombinase-induced Clotting Time test (PiCT) is necessary for in vitro evaluation of fondaparinux and to be avoided for the reversible, direct factor Xa inhibitor, rivaroxaban.

Kluft C, Meijer P, Kret R, Burggraaf J

International journal of laboratory hematology, 2013 Jul; 35(4):379-84

View publication
Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk-benefit.

Heuberger JA, Cohen Tervaert JM, Schepers FM, Vliegenthart AD, Rotmans JI, Daniels JM, Burggraaf J, Cohen AF

British journal of clinical pharmacology, 2013 May; 75(6):1406-21

View publication
Evaluation of a bedside device to assess the activated partial thromboplastin time for heparin monitoring in infants.

Klein RH, van der Vorst MM, de Wilde RB, Hogenbirk K, de Kam ML, Burggraaf J

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2013 Mar; 24(3):327-31

View publication
Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives: a rebuttal.

Kluft C, Skouby SO, Jespersen J, Burggraaf J

Journal of thrombosis and haemostasis : JTH, 2013 Jan; 11(2):394-5

View publication

«
1
2
3
4
5
»